NOVAREL^® (chorionic gonadotropin for injection, USP) is a human chorionic gonadotropin (hCG) that is used to stimulate egg release (ovulation) in the infertile woman who has not ovulated, and whose cause of infertility is not due to primary ovarian failure. Before administering NOVAREL^®, patients have usually received previous treatment with gonadotropins, such as BRAVELLE^® (urofollitropin for injection, purified) , MENOPUR^® (menotropins for injection, USP) , or REPRONEX^® (menotropins for injection, USP) .

NOVAREL^® is available by prescription in 10 mL multiple-dose vials containing 10,000 USP units with accompanying diluent.

Please note:
NOVAREL^® should be used in conjunction with urofollitropin or human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions, and adverse reactions described in the package insert for gonadotropins. The principal serious adverse reactions are: (1) ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion, (2) enlargement or rupture of ovarian cysts with resultant hemoperitoneum, (3) multiple births, and (4) arterial thromboembolism.

Please click here to see the side effects, contraindications, and other full Prescribing Information.

Previous: REPRONEX® FAQs

Next: Using NOVAREL®